Company halts development of experimental depression treatment
- Neurocrine Biosciences shares dropped 4.7% premarket after two clinical trial failures
- Experimental epilepsy treatment and investigational treatment for anhedonia in major depressive disorder both failed
- No further development planned for the drugs
- Analysts say the failures are likely to stunt momentum for Neurocrine
- Neurocrine shares are down 6.1% in the year to date
Neurocrine Biosciences Inc. shares fell 4.7% premarket after the company announced two clinical trial failures. An experimental epilepsy treatment and an investigational treatment for anhedonia in major depressive disorder both failed to meet their primary goals. As a result, Neurocrine will not be continuing development of these drugs. Analysts believe that these failures will likely stunt the company’s momentum. Neurocrine shares are down 6.1% in the year to date.
Factuality Level: 8
Factuality Justification: The article provides information about Neurocrine Biosciences Inc. announcing two clinical trial failures for an epilepsy treatment and a treatment for major depressive disorder. It includes quotes from the company’s chief medical officer and an analyst’s report. The information provided is specific and does not contain any obvious bias or opinion masquerading as fact. However, the article is short and lacks in-depth analysis or additional context.
Noise Level: 3
Noise Justification: The article provides relevant information about Neurocrine Biosciences Inc.’s clinical trial failures and the impact on their stock. It includes quotes from the company’s chief medical officer and an analyst’s report. However, there is some filler content at the beginning of the article about text-to-speech technology and a request for feedback.
Financial Relevance: Yes
Financial Markets Impacted: Neurocrine Biosciences Inc. shares
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to the financial performance of Neurocrine Biosciences Inc. and its impact on the company’s shares. There is no mention of an extreme event.
Public Companies: Neurocrine Biosciences Inc. (NBIX), Takeda Pharmaceutical Co. Ltd. (TAK)
Key People: Dr. Eiry Roberts (Neurocrine’s chief medical officer), Evan David Seigerman (BMO Capital Markets analyst)
Reported publicly:
www.marketwatch.com 
